424 related articles for article (PubMed ID: 8113390)
1. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1.
Miyata T; Inagi R; Iida Y; Sato M; Yamada N; Oda O; Maeda K; Seo H
J Clin Invest; 1994 Feb; 93(2):521-8. PubMed ID: 8113390
[TBL] [Abstract][Full Text] [Related]
2. Beta 2-microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: role in the pathogenesis of hemodialysis-associated amyloidosis.
Iida Y; Miyata T; Inagi R; Sugiyama S; Maeda K
Biochem Biophys Res Commun; 1994 Jun; 201(3):1235-41. PubMed ID: 8024566
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycation end products stimulate tumor necrosis factor-alpha and interleukin-1 beta secretion by peritoneal macrophages in patients on continuous ambulatory peritoneal dialysis.
Rashid G; Korzets Z; Bernheim J
Isr Med Assoc J; 2006 Jan; 8(1):36-9. PubMed ID: 16450750
[TBL] [Abstract][Full Text] [Related]
4. beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis.
Miyata T; Oda O; Inagi R; Iida Y; Araki N; Yamada N; Horiuchi S; Taniguchi N; Maeda K; Kinoshita T
J Clin Invest; 1993 Sep; 92(3):1243-52. PubMed ID: 8376584
[TBL] [Abstract][Full Text] [Related]
5. New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced glycation end products in renal failure.
Miyata T
Nihon Jinzo Gakkai Shi; 1996 May; 38(5):191-7. PubMed ID: 8699608
[TBL] [Abstract][Full Text] [Related]
6. Glycation of human beta 2-microglobulin in patients with hemodialysis-associated amyloidosis: identification of the glycated sites.
Miyata T; Inagi R; Wada Y; Ueda Y; Iida Y; Takahashi M; Taniguchi N; Maeda K
Biochemistry; 1994 Oct; 33(40):12215-21. PubMed ID: 7918443
[TBL] [Abstract][Full Text] [Related]
7. Monocyte/macrophage response to beta 2-microglobulin modified with advanced glycation end products.
Miyata T; Iida Y; Ueda Y; Shinzato T; Seo H; Monnier VM; Maeda K; Wada Y
Kidney Int; 1996 Feb; 49(2):538-50. PubMed ID: 8821842
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-beta is involved in the pathogenesis of dialysis-related amyloidosis.
Matsuo K; Ikizler TA; Hoover RL; Nakamoto M; Yasunaga C; Pupim LB; Hakim RM
Kidney Int; 2000 Feb; 57(2):697-708. PubMed ID: 10652049
[TBL] [Abstract][Full Text] [Related]
9. Role of uremic and endothelial factors in the development of beta 2-microglobulin amyloidosis.
Nakashima Y; Akizawa T; Nagai T; Koshikawa S
Kidney Int Suppl; 1993 Jun; 41():S88-95. PubMed ID: 8320954
[TBL] [Abstract][Full Text] [Related]
10. Ultrastructural localization of advanced glycation end products and beta2-microglobulin in dialysis amyloidosis.
Brancaccio D; Gallieni M; Niwa T; Braidotti P; Coggi G
J Nephrol; 2000; 13(2):129-36. PubMed ID: 10858976
[TBL] [Abstract][Full Text] [Related]
11. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis.
Miyata T; Hori O; Zhang J; Yan SD; Ferran L; Iida Y; Schmidt AM
J Clin Invest; 1996 Sep; 98(5):1088-94. PubMed ID: 8787669
[TBL] [Abstract][Full Text] [Related]
12. beta(2)-Microglobulin modified with advanced glycation end products delays monocyte apoptosis.
Hou FF; Miyata T; Boyce J; Yuan Q; Chertow GM; Kay J; Schmidt AM; Owen WF
Kidney Int; 2001 Mar; 59(3):990-1002. PubMed ID: 11231354
[TBL] [Abstract][Full Text] [Related]
13. Beta 2-microglobulin induces stromelysin production by human synovial fibroblasts.
Migita K; Eguchi K; Tominaga M; Origuchi T; Kawabe Y; Nagataki S
Biochem Biophys Res Commun; 1997 Oct; 239(2):621-5. PubMed ID: 9344881
[TBL] [Abstract][Full Text] [Related]
14. Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts.
Owen WF; Hou FF; Stuart RO; Kay J; Boyce J; Chertow GM; Schmidt AM
Kidney Int; 1998 May; 53(5):1365-73. PubMed ID: 9573554
[TBL] [Abstract][Full Text] [Related]
15. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study.
Traut M; Haufe CC; Eismann U; Deppisch RM; Stein G; Wolf G
Blood Purif; 2007; 25(5-6):432-40. PubMed ID: 17957097
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous and lingual papules as a sign of beta 2 microglobulin-derived amyloidosis in a long-term hemodialysis patient.
Uenotsuchi T; Imafuku S; Nagata M; Kiryu H; Morita K; Koga T; Furue M
Eur J Dermatol; 2003; 13(4):393-5. PubMed ID: 12948922
[TBL] [Abstract][Full Text] [Related]
17. Haemodialysis-associated beta 2M amyloidosis: current controversies.
Stein G; Sperschneider H; Fünfstück R; Ritz E
Nephrol Dial Transplant; 1994; 9 Suppl 3():48-50. PubMed ID: 8072726
[TBL] [Abstract][Full Text] [Related]
18. Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis.
Wanidworanun C; Strober W
J Immunol; 1993 Dec; 151(12):6853-61. PubMed ID: 8258695
[TBL] [Abstract][Full Text] [Related]
19. Involvement of peripheral blood monocytes in haemodialysis: in vivo induction of tumour necrosis factor alpha, interleukin 6 and beta 2-microglobulin.
Pertosa G; Marfella C; Tarantino EA; Di Cillo M; Manno C; Russo R; Schena FP
Nephrol Dial Transplant; 1991; 6 Suppl 2():18-23. PubMed ID: 1866063
[TBL] [Abstract][Full Text] [Related]
20. Long-term complications of dialysis: pathogenic factors with special reference to amyloidosis.
Gejyo F; Homma N; Arakawa M
Kidney Int Suppl; 1993 Jun; 41():S78-82. PubMed ID: 8320951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
